Saakshi Medtech shareholders approve capital increase at EGM

1 min read     Updated on 05 Jun 2026, 09:31 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Saakshi Medtech and Panels Limited received shareholder approval to increase its authorized capital and issue equity shares on a preferential basis during an EGM held on June 2, 2026. The resolutions passed with 13,520,900 votes in favor, representing 76.58% of total outstanding shares, with no votes against. The voting results were scrutinized by Jay Pandya & Associates and submitted to the National Stock Exchange of India Limited on June 4, 2026.

powered bylight_fuzz_icon
42001450

*this image is generated using AI for illustrative purposes only.

Saakshi Medtech and Panels Limited secured shareholder approval to increase its authorized capital and issue equity shares on a preferential basis during an Extra-Ordinary General Meeting (EGM) held on June 2, 2026. The resolutions were passed with a requisite majority, with 13,520,900 votes polled representing 76.58% of the total outstanding shares. There were no votes cast against any of the resolutions. Mrs. Mayuri Aniket Latkar, Chief Financial Officer and Whole-time Director, submitted the voting results to the National Stock Exchange of India Limited on June 4, 2026, under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Results

The remote e-voting process was scrutinized by Jay Pandya, Proprietor of M/s. Jay Pandya & Associates, Company Secretaries. The voting period remained open from May 29, 2026, to June 1, 2026. The promoter group, holding 13,210,100 shares, participated fully via e-voting, while public shareholders also cast their votes through the remote e-voting facility.

Resolutions Passed

Sr. No. Particulars of Resolution Nature of Resolution Votes in Favor Votes Against
1. Increase in Authorized Capital and consequential alteration in the Capital Clause of Memorandum of Association Ordinary Resolution 13,520,900 0
2. Approval of issue of Equity Shares on Preferential Basis for consideration other than cash Special Resolution 13,520,900 0

Meeting Details

The EGM commenced at 03:00 P.M. and concluded at 03:19 P.M. on June 2, 2026. The company confirmed that neither the promoters nor the promoter group were interested in the agenda or resolutions presented. The results of the remote e-voting were announced within the stipulated timeframe and intimated to the stock exchanges.

Historical Stock Returns for Saakshi Medtech & Panels

1 Day5 Days1 Month6 Months1 Year5 Years
-0.08%+4.15%-4.74%+25.06%+44.54%+60.47%

What specific strategic acquisitions or investments does Saakshi Medtech plan to fund through the preferential issue of equity shares?

How will the dilution of existing shareholding impact the company's earnings per share and stock valuation in the short term?

Who are the potential investors likely to participate in the preferential allotment, and what expertise or value will they bring?

Saakshi Medtech & Panels
View Company Insights
View All News
like20
dislike

Saakshi Medtech FY26 net profit rises 161% to ₹1228.97 crore

2 min read     Updated on 27 May 2026, 02:01 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Saakshi Medtech and Panels Limited reported a 161% rise in net profit to ₹1228.97 crore for FY26, with revenue increasing to ₹11550.64 crore. The audited results, approved by the Board on May 26, 2026, received an unmodified opinion from statutory auditors. Total assets grew to ₹15698.63 crore, supported by strong operating cash flows of ₹1758.36 crore.

powered bylight_fuzz_icon
41373051

*this image is generated using AI for illustrative purposes only.

Saakshi Medtech and Panels Limited reported a significant surge in financial performance for the financial year ended March 31, 2026, with net profit rising 161% to ₹1228.97 crore. The company’s revenue from operations increased to ₹11550.64 crore, up from ₹9243.11 crore in the previous year, driven by growth in its manufacturing segment. The Board of Directors approved the audited standalone financial results during its meeting held on May 26, 2026, following recommendations from the Audit Committee.

The statutory auditors, M/s. Kishor Gujar and Associates, issued an audit report with an unmodified opinion on the financial results. The auditors confirmed that the results present a true and fair view in conformity with the recognition and measurement principles laid down in Accounting Standard (AS) 25. The company operates in a single business segment, Manufacturing, and is exempt from adopting Indian Accounting Standards (IndAS) as it is listed on an SME Exchange.

Total income for the year stood at ₹11604.44 crore, compared to ₹9300.33 crore in FY25. The company managed its expenses effectively, with total expenses for the year at ₹9937.73 crore, up from ₹8641.48 crore in the prior year. Profit before tax for the year ended March 31, 2026, was ₹1666.71 crore, a significant increase from ₹658.85 crore in the previous year. The basic and diluted earnings per share (EPS) for the year were recorded at ₹6.96, compared to ₹2.67 in FY25.

The company’s balance sheet reflects a strengthening of its asset base. Total assets increased to ₹15698.63 crore as of March 31, 2026, from ₹13133.37 crore in the previous year. Shareholders' funds grew to ₹11033.44 crore, driven by an increase in reserves and surplus to ₹9267.84 crore. Non-current assets, primarily comprising property, plant, and equipment, stood at ₹9566.62 crore, while current assets were recorded at ₹6132.02 crore.

Cash flow from operating activities improved to ₹1758.36 crore for the year, compared to ₹302.26 crore in FY25. However, the company invested heavily in expanding its asset base, resulting in a net cash outflow of ₹2534.11 crore from investing activities. Cash and cash equivalents at the end of the year stood at ₹179.61 crore. The Board confirmed that there were no exceptional or extraordinary items during the reporting period and that no investor complaints were pending or received during the year.

Financial Results for FY26

Particulars Year Ended 31 March 2026 (₹ in Lakhs) Year Ended 31 March 2025 (₹ in Lakhs)
Revenue from Operations 11,550.64 9,243.11
Total Income 11,604.44 9,300.33
Total Expenses 9,937.73 8,641.48
Profit Before Tax 1,666.71 658.85
Net Profit 1,228.97 470.99
Basic EPS (₹) 6.96 2.67

Historical Stock Returns for Saakshi Medtech & Panels

1 Day5 Days1 Month6 Months1 Year5 Years
-0.08%+4.15%-4.74%+25.06%+44.54%+60.47%

How does Saakshi Medtech plan to sustain the 161% profit growth given the heavy capital expenditure?

Will the company's exemption from Ind-AS impact its ability to attract institutional investors or move to the main board?

What specific capacity expansions or acquisitions are driving the ₹2534 crore cash outflow in investing activities?

Saakshi Medtech & Panels
View Company Insights
View All News
like16
dislike

More News on Saakshi Medtech & Panels

1 Year Returns:+44.54%